Increased myo-inositol in parietal white and gray matter as a biomarker of poor prognosis in neuropsychiatric lupus: A case report

Lupus

Volumn 23, Issue 10, 2014, Pages 1073-1078

  Castillo, A Guillen Del ^a   Alonso, J ^b   Martinez Valle F ^a   Alonso Vila, S ^a   Garrido Castro, A C ^a   Vilardell Tarres M ^a   Rovira, A ^b   Ordi Ros, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Cognitive impairment; Myo inositol; N acetylaspartate; Neuropsychiatric lupus; Proton magnetic resonance spectroscopy; Systemic lupus erythematosus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATINE; CYCLOPHOSPHAMIDE; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN; INOSITOL; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

ADULT; AKINESIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN CORTEX ATROPHY; BRAIN DISEASE; BRAIN SIZE; CASE REPORT; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRAY MATTER; HAND TREMOR; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPOCOMPLEMENTEMIA; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; MAINTENANCE THERAPY; MEMORY DISORDER; MIDDLE AGED; MUTISM; NEUROLOGIC DISEASE; NEUROPSYCHIATRIC LUPUS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PANCYTOPENIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEINURIA; PROTON NUCLEAR MAGNETIC RESONANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT DURATION; VASCULITIS; WHITE MATTER; ATROPHY; COGNITION; DISEASE COURSE; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; METABOLISM; PARIETAL LOBE; PATHOLOGY; PSYCHOLOGY; TEMPORAL LOBE; TIME; UPREGULATION;

ATROPHY; BIOLOGICAL MARKERS; COGNITION; DISEASE PROGRESSION; FEMALE; GRAY MATTER; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INOSITOL; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PARIETAL LOBE; PROTON MAGNETIC RESONANCE SPECTROSCOPY; TEMPORAL LOBE; TIME FACTORS; UP-REGULATION; WHITE MATTER;

EID: 84906699215     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314534303     Document Type: Article

References (28)

1. Unterman A Nolte JE Boaz M Abady M Shoenfeld Y Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: A meta-analysis. Semin Arthritis Rheum 2011; 41: 1-11.
2. Sibbitt WL Jr. Brooks WM Kornfeld M Hart BL Bankhurst AD Roldan CA. Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum 2010; 40: 32-52.
3. The American College of Rheumatology. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608.
4. Borowoy AM Pope JE Silverman E et al. Neuropsychiatric lupus: The prevalence and autoantibody associations depend on the definition: Results from the 1000 faces of lupus cohort. Semin Arthritis Rheum 2012; 42: 179-185.
5. Kozora E Brown MS Filley CM et al. Memory impairment associated with neurometabolic abnormalities of the hippocampus in patients with non-neuropsychiatric systemic lupus erythematosus. Lupus 2011; 20: 598-606.
6. Tan EM Cohen AS Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
7. Gladman DD Iban ez D Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-291.
8. Gladman DD Urowitz MB Goldsmith CH et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 809-813.
9. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30: 672-679.
10. Barile-Fabris L Ariza-Andraca R Olguín-Ortega L et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 620-625.
11. Tokunaga M Saito K Kawabata D et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66: 470-475.
12. Narvá ez J Ríos-Rodriguez V de la Fuente D et al. Rituximab therapy in refractory neuropsychiatric lupus: Current clinical evidence. Semin Arthritis Rheum 2011; 41: 364-372.
13. Castellino G Govoni M Padovan M Colamussi P Borrelli M Trotta F. Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: A functional multi-imaging approach and follow up. Ann Rheum Dis 2005; 64: 1022-1027.
14. Govoni M Castellino G Padovan M Borrelli M Trotta F. Recent advances and future perspective in neuroimaging in neuropsychiatric systemic lupus erythematosus. Lupus 2004; 13: 149-158.
15. Kozora E Filley CM. Cognitive dysfunction and white matter abnormalities in systemic lupus erythematosus. J Int Neuropsychol Soc 2011; 17: 385-392.
16. Peterson PL Howe FA Clark CA Axford JS. Quantitative magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus. Lupus 2003; 12: 897-902.
17. Zimny A Szmyrka-Kaczmarek M Szewczyk P et al. In vivo evaluation of brain damage in the course of systemic lupus erythematosus using magnetic resonance spectroscopy perfusionweighted and diffusion-tensor imaging. Lupus 2014; 23: 10-19.
18. Bitsch A Bruhn H Vougioukas V et al. Inflammatory CNS demyelination: Histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 1999; 20: 1619-1627.
19. Brooks WM Sibbitt Jr. WL Kornfeld M Jung RE Bankhurst AD Roldan CA. The histopathologic associates of neurometabolite abnormalities in fatal neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2010; 62: 2055-2063.
20. Appenzeller S Li LM Costallat LT Cendes F. Evidence of reversible axonal dysfunction in systemic lupus erythematosus: A proton MRS study. Brain 2005; 128: 2933-2940.
21. Brooks WM Jung RE Ford CC Greinel EJ Sibbitt Jr. WL. Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus. J Rheumatol 1999; 26: 81-85.
22. Axford JS Howe FA Heron C Griffiths JR. Sensitivity of quantitative (1)H magnetic resonance spectroscopy of the brain in detecting early neuronal damage in systemic lupus erythematosus. Ann Rheum Dis 2001; 60: 106-111.
23. Valenzuela MJ Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001; 56: 592-598.
24. Herminghaus S Frolich L Gorriz C et al. Brain metabolism in Alzheimer disease and vascular dementia assessed by in vivo proton magnetic resonance spectroscopy. Psychiatry Res 2003; 123: 183-190.
25. Kantarci K Knopman DS Dickson DW et al. Alzheimer disease: Postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 2008; 248: 210-220.
26. Brand A Richter-Landsberg C Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993; 15: 289-298.
27. Urenjak J Williams SR Gadian DG Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993; 13: 981-989.
28. Kowal C DeGiorgio LA Nakaoka T et al. Cognition and immunity; antibody impairs memory. Immunity 2004; 21: 179-188.